Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Average Target Price of $12.77

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned a consensus rating of “Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $12.77.

Several equities analysts recently issued reports on the stock. Robert W. Baird boosted their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Citizens Jmp reiterated a “market outperform” rating and set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, September 21st. Needham & Company LLC restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th. Finally, Pivotal Research set a $14.00 price objective on Taysha Gene Therapies in a report on Tuesday, June 23rd.

Taysha Gene Therapies Price Performance

Shares of Taysha Gene Therapies stock opened at $4.49 on Wednesday. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.46 billion, a PE ratio of -10.69 and a beta of 1.19. The business has a 50 day moving average of $5.50 and a 200 day moving average of $5.69. Taysha Gene Therapies has a 52 week low of $3.69 and a 52 week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TSHA. Polar Capital Holdings Plc lifted its holdings in shares of Taysha Gene Therapies by 49.8% during the fourth quarter. Polar Capital Holdings Plc now owns 7,931,403 shares of the company’s stock valued at $43,623,000 after purchasing an additional 2,637,524 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Taysha Gene Therapies by 534.7% in the 2nd quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company’s stock worth $27,074,000 after buying an additional 3,349,244 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $20,471,000. ADAR1 Capital Management LLC grew its position in Taysha Gene Therapies by 19.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock valued at $13,318,000 after purchasing an additional 483,620 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Taysha Gene Therapies by 178.5% during the first quarter. SG Americas Securities LLC now owns 2,176,742 shares of the company’s stock valued at $9,730,000 after buying an additional 1,395,268 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.